Prof. Neelika Malavige selected as a member of WHO technical advisory committee on Covid-19

Prof. Neelika Malavige was selected as a member of WHO technical advisory committee on Covid-19. WHO(World Health Organization) has established a Technical Advisory Group (TAG) to advise on scientific, technical and strategic matters related to the COVID-19 Technology Access Pool (C-TAP). The group is composed of 10 renowned experts with a diverse range of knowledge and expertise as clinicians and researchers working on COVID-19 health products; experts in access to medicines, diagnostics, vaccines and other health products; specialists of public health-oriented intellectual property; technology transfer experts; business development experts; experts in pricing, procurement, needs estimation and/or regulation of medicines.

USJ Congratulates Prof. Neelika Malavige on the well deserved position as a member of WHO technical advisory committee, recognizing the tireless efforts in fighting Covid-19 pandemic. The University of Sri Jayewardenepura wishes her all the best for all her future endeavors.

News source :  https://www.who.int/groups/who-technical-advisory-group-on-the-covid-19-technology-access-pool-(c-tap)

 

 

Read research articles of Prof. Neelika Malavige :

90 percent of the new cases in Colombo belonged to the Delta variant says Dr. Jeewandara

Over 95% individuals developed antibodies against the Sinopharm vaccine – USJ Researchers

Research on Immunological response to COVID-19 vaccines by the Department of Immunology and Molecular Medicine, USJ

Single dose of Sputnik V is highly effective but second dose is beneficial says USJ researchers

USJ researchers found Four mutant Covid Delta variants with two new Sri Lankan mutations (A701S, R24C)

Delta variant was responsible for 95.8% of Covid-19 infections in Sri Lanka – Allergy, Immunology Cell Biology Unit, USJ

Whole genomic sequencing of the SARS-CoV-2 variants in Sri Lanka issued by Dept. of Immunology and Molecular Medicine USJ

The delta variant in Sri Lanka assigned a new sub-lineage (AY.28)

Antibody responses declined but T cell responses remained 12 weeks after Sinopharm second dose – USJ research

Category Posts